Chinese Academy of

Levamisole hydrochloride (brand: ERGAMISOL) is a small-molecule oral therapeutic being investigated by Xiyuan Hospital of China Academy of Chinese Medical Sciences for the treatment of anemia. The program, designated ZXMZ2012, is currently in Phase 2 development. Levamisole is an established pharmaceutical entity with prior US FDA approval (NDA020035) under Janssen Pharma for other indications. The mechanism of action and specific molecular target for this anemia indication have not yet been disclosed. The most recent program milestone was recorded on April 19, 2012. The sponsor is evaluating levamisole's potential in a competitive anemia treatment landscape that includes iron supplementation, erythropoiesis-stimulating agents, and emerging therapies. Development status remains active, though no expected next milestone date has been publicly announced. The clinical evidence base is being established through at least one Phase 2 trial registered with the US National Institutes of Health (NCT01579110).

Anemia represents a significant global health burden affecting hundreds of millions of patients across multiple etiologies, including chronic kidney disease, chemotherapy-induced anemia, and iron deficiency. Current standard-of-care therapies include iron supplementation, erythropoiesis-stimulating agents (ESAs), and newer agents targeting erythroid maturation. Despite available treatments, substantial unmet medical need persists due to treatment resistance, tolerability concerns, cardiovascular risk associations with ESAs, and the need for alternative mechanisms of action. Levamisole's investigation in this indication suggests potential immunomodulatory or hematopoietic mechanisms that may differentiate it from existing therapies. The competitive landscape includes well-established agents such as epoetin alfa and beta (Hoffmann-La Roche), ferric carboxymaltose (United Therapeutics), and emerging Phase 3 candidates including mitapivat (Lacuna Pharma) and luspatercept-based therapies (Celgene). A successful Phase 2 outcome could position levamisole as an alternative therapeutic option, particularly if it demonstrates efficacy in patient populations resistant to conventional treatments or offers improved safety or tolerability profiles. The Chinese sponsor's focus on this indication reflects regional clinical priorities and potential market opportunities in Asia-Pacific regions.

Drug Class: Immunomodulatory small molecule (historical anthelmintic with immunomodulatory properties)

Modality: Small molecule

Route of Administration: Oral

Molecular Target: Not yet disclosed

Mechanism of Action: Not yet disclosed for this anemia indication

Brand Name: ERGAMISOL

International Nonproprietary Name (INN): Levamisole hydrochloride

Regulatory History: Levamisole hydrochloride was previously approved by the US FDA (NDA020035) under Janssen Pharma sponsorship for other indications. The current anemia indication represents a new therapeutic application.

Related Therapies in Development: The anemia treatment space includes iron replacement agents (ferric carboxymaltose, ferumoxytol), erythropoiesis-stimulating agents (epoetin alfa, epoetin beta, darbepoetin alfa), and emerging targeted therapies such as mitapivat and luspatercept.

United States (FDA): Levamisole hydrochloride (ERGAMISOL) holds a prior FDA approval (NDA020035) under Janssen Pharma for non-anemia indications. The current Phase 2 anemia program has not yet disclosed FDA regulatory pathway or IND status.

China (NMPA): The program is sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences, suggesting potential focus on Chinese regulatory approval; specific NMPA regulatory status not yet disclosed.

European Medicines Agency (EMA): Regulatory status in Europe not yet disclosed.

Japan (PMDA): Regulatory status in Japan not yet disclosed.

Current Status: Program remains in active Phase 2 development. No filing, approval, or label expansion information has been disclosed. Expected regulatory milestones and timelines are not yet publicly available.

Strategic Implications: The sponsorship by a Chinese academic medical center (Xiyuan Hospital of China Academy of Chinese Medical Sciences) suggests this program may prioritize Chinese market development and regulatory approval. The oral small-molecule format offers potential advantages in patient convenience and manufacturing scalability compared to injectable therapies.

Clinical Development Status: The program has remained in Phase 2 since at least April 2012, with no publicly disclosed advancement to Phase 3 or regulatory filing. The extended Phase 2 duration without announced progression suggests either slower-than-expected enrollment, efficacy/safety findings requiring additional investigation, or resource constraints. The lack of disclosed mechanism of action and target limits competitive differentiation assessment.

Competitive Positioning Challenges: Levamisole faces entrenched competition from well-established ESAs (epoetin alfa/beta, darbepoetin) with decades of clinical experience and proven efficacy, as well as newer targeted agents (mitapivat, luspatercept) with disclosed mechanisms and Phase 3 data. Without clear mechanistic differentiation or superior efficacy/safety profile, market penetration may be limited.

Future Catalysts: Key catalysts include Phase 2 data publication or presentation, advancement to Phase 3, disclosure of mechanism of action, regulatory pathway clarification, and potential partnership announcements. The absence of expected next milestone dates limits visibility into near-term development trajectory.

Patent and Commercial Considerations: Patent status and expected loss-of-exclusivity dates are not disclosed. Given levamisole's prior approval history, patent protection for this new indication may be limited unless novel formulations or combinations are pursued.